Riskpilot← Back to searchSign inGet full accessBioScandinavia AB
ABActiveOrg 5591078083Karl Xi Gatan 19 BComputer programming activities · NACE 6210Est. 20170 employees
Revenue 2024
SEK 0
EBITDA margin
—
-103% vs 2023
Equity ratio
59.9%
Financial strength
Net profit 2024
SEK 1K
-99% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -11K | -103% |
| Net profit | SEK 1K | -99% |
| Total assets | SEK 194K | -73% |
| Equity | SEK 117K | -63% |
| Employees | 0 | — |
Legal name
BioScandinavia AB
Org number
5591078083
Legal form
Aktiebolag
NACE code
6210 · Computer programming activities
Founded
5 april 2017
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget ska bedriva medicinsk och medicinteknisk forskning och utveckling, inkl hälsoinriktad prevention samt it-app och liknande lösningar. Investera i och driva bolag inom livsvetenskaper och medicinteknik samt driva ett Life Science Foresight Institute. Handel med och förvaltning av värdepapper, fastigheter och fastighetsförvalning, och därmed förenlig verksamhet.
Address
Karl Xi Gatan 19 B
Email
andersson.eric@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 49 | 0 | 1 222 | 426 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 49 | −6 | 555 | 337 | −11 |
| Depreciation & amort. | −0 | −0 | — | — | — |
| EBIT | 49 | −6 | 555 | 337 | −11 |
| Net financials | — | — | −1 | −2 | −5 |
| Profit before tax | 37 | −1 | 554 | 251 | 4 |
| Tax | −8 | −0 | −114 | −52 | −2 |
| Net profit | 29 | −1 | 439 | 199 | 1 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 110 | 91 | 775 | 722 | 194 |
| Equity | 78 | 77 | 517 | 315 | 117 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 20 | 8 | 252 | 316 | 7 |
| Total debt | 20 | 8 | 252 | 316 | 7 |
EBITDA margin
-1101700.0%
This company
15.8%
Market median
-6972885% vs market
20202024
Equity ratio
59.9%
This company
38.2%
Market median
+57% vs market
20202024
Return on equity
1.0%
This company
18.4%
Market median
-95% vs market
20202024
Net profit margin
118700.0%
This company
8.1%
Market median
+1465332% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.67×
This company
0.62×
Market median
+8% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Former (2) | ||
PO Chief Auditor | Chief Auditor | 2022 – 2022 |
BÅ Chief Auditor | Chief Auditor | 2022 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of BioScandinavia AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Pär-Ola Olsson | Chief Auditor | 0 companies |
| Bengt Åke Olsson | Chief Auditor | 0 companies |
| Eric Hampus Andersson | Board of Directors | 0 companies |
| Gert Roland Andersson | Deputy Board Member | 0 companies |